{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:29:31Z","timestamp":1790368171686,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.healun.2016.06.019","type":"journal-article","created":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T15:01:13Z","timestamp":1466780473000},"page":"193-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Transition from parenteral to oral treprostinil in pulmonary arterial hypertension"],"prefix":"10.1016","volume":"36","author":[{"given":"Murali M.","family":"Chakinala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Rischard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mathier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Leedom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Laliberte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. James","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2016.06.019_bib1","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1161\/CIRCULATIONAHA.114.006974","article-title":"Advances in therapeutic interventions for patients with pulmonary arterial hypertension","volume":"130","author":"Humbert","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2016.06.019_bib2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"Galie","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.healun.2016.06.019_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2016.06.019_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.06.019_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1086\/674304","article-title":"Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics","volume":"3","author":"White","year":"2013","journal-title":"Pulm Circ"},{"key":"10.1016\/j.healun.2016.06.019_bib6","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.healun.2010.06.013","article-title":"Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations","volume":"29","author":"Mathier","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.06.019_bib7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1378\/chest.126.3.808","article-title":"Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension","volume":"126","author":"Suleman","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.healun.2016.06.019_bib8","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1378\/chest.130.5.1471","article-title":"Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study","volume":"130","author":"Steiner","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.healun.2016.06.019_bib9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/FJC.0b013e31828685da","article-title":"Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension","volume":"61","author":"White","year":"2013","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.healun.2016.06.019_bib10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1378\/chest.06-2118","article-title":"Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial","volume":"132","author":"Rubenfire","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.healun.2016.06.019_bib11","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.healun.2007.07.040","article-title":"Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension","volume":"26","author":"Keogh","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.06.019_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4103\/2045-8932.114768","article-title":"A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost","volume":"3","author":"Channick","year":"2013","journal-title":"Pulmon Circul"},{"key":"10.1016\/j.healun.2016.06.019_bib13","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.amjcard.2012.07.012","article-title":"Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension","volume":"110","author":"de Jesus Perez","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.healun.2016.06.019_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11136-005-3513-4","article-title":"The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension","volume":"15","author":"McKenna","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1016\/j.healun.2016.06.019_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.healun.2007.10.004","article-title":"United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)","volume":"27","author":"Gomberg-Maitland","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.06.019_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.healun.2016.06.019_bib17","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","article-title":"Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial","volume":"142","author":"Tapson","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.healun.2016.06.019_bib18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","article-title":"Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial","volume":"127","author":"Jing","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2016.06.019_bib19","doi-asserted-by":"crossref","DOI":"10.1378\/chest.1963063","article-title":"A pharmacokinetic and tolerability comparison in subjects transitioning from twice daily to three times daily dosing of oral treprostinil","volume":"146","author":"White","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.healun.2016.06.019_bib20","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.healun.2016.06.019_bib21","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.healun.2013.08.010","article-title":"Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry","volume":"32","author":"Farber","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2016.06.019_bib22","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1378\/chest.07-1992","article-title":"Transition from IV to subcutaneous prostacyclin: premature withdrawal?","volume":"132","author":"Shapiro","year":"2007","journal-title":"Chest"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249816301978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249816301978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:33:22Z","timestamp":1760949202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249816301978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S1053249816301978"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2016.06.019","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transition from parenteral to oral treprostinil in pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2016.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author. Published by Elsevier Inc. on behalf of International Society for the Heart and Lung Transplantation","name":"copyright","label":"Copyright"}]}}